Thyroid and Cardiovascular Disease: Research Agenda for Enhancing Knowledge, Prevention, and Treatment

Anne R. Cappola, Akshay S. Desai, Marco Medici, Lawton S. Cooper, Debra Egan, George Sopko, Glenn I. Fishman, Steven Goldman, David S. Cooper, Samia Mora, Peter J. Kudenchuk, Anthony N. Hollenberg, Cheryl L. McDonald, Paul W. Ladenson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Thyroid hormones have long been known to have a range of effects on the cardiovascular system. However, significant knowledge gaps exist concerning the precise molecular and biochemical mechanisms governing these effects and the optimal strategies for management of abnormalities in thyroid function in patients with and without preexisting cardiovascular disease. In September 2017, The National Heart, Lung, and Blood Institute convened a Working Group with the goal of developing priorities for future scientific research relating thyroid dysfunction to the progression of cardiovascular disease. The Working Group reviewed and discussed the roles of normal thyroid physiology, the consequences of thyroid dysfunction, and the effects of therapy in three cardiovascular areas: cardiac electrophysiology and arrhythmias, the vasculature and atherosclerosis, and the myocardium and heart failure. This report describes the current state of the field, outlines barriers and challenges to progress, and proposes research opportunities to advance the field, including strategies for leveraging novel approaches using omics and big data. The Working Group recommended research in three broad areas: 1) investigation into the fundamental biology relating thyroid dysfunction to the development of cardiovascular disease and into the identification of novel biomarkers of thyroid hormone action in cardiovascular tissues; 2) studies that define subgroups of patients with thyroid dysfunction amenable to specific preventive strategies and interventional therapies related to cardiovascular disease; and 3) clinical trials focused on improvement in cardiovascular performance and cardiovascular outcomes through treatment with thyroid hormone or thyromimetic drugs.

Original languageEnglish (US)
Pages (from-to)760-777
Number of pages18
JournalThyroid
Volume29
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Thyroid Diseases
Thyroid Gland
Cardiovascular Diseases
Thyroid Hormones
Research
Therapeutics
Cardiac Electrophysiology
National Heart, Lung, and Blood Institute (U.S.)
Preexisting Condition Coverage
Cardiovascular System
Cardiac Arrhythmias
Atherosclerosis
Myocardium
Heart Failure
Biomarkers
Clinical Trials
Pharmaceutical Preparations

Keywords

  • arrhythmia
  • atherosclerosis
  • heart failure
  • lipid
  • low T3 syndrome
  • subclinical hyperthyroidism
  • subclinical hypothyroidism

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Cappola, A. R., Desai, A. S., Medici, M., Cooper, L. S., Egan, D., Sopko, G., ... Ladenson, P. W. (2019). Thyroid and Cardiovascular Disease: Research Agenda for Enhancing Knowledge, Prevention, and Treatment. Thyroid, 29(6), 760-777. https://doi.org/10.1089/thy.2018.0416

Thyroid and Cardiovascular Disease : Research Agenda for Enhancing Knowledge, Prevention, and Treatment. / Cappola, Anne R.; Desai, Akshay S.; Medici, Marco; Cooper, Lawton S.; Egan, Debra; Sopko, George; Fishman, Glenn I.; Goldman, Steven; Cooper, David S.; Mora, Samia; Kudenchuk, Peter J.; Hollenberg, Anthony N.; McDonald, Cheryl L.; Ladenson, Paul W.

In: Thyroid, Vol. 29, No. 6, 01.06.2019, p. 760-777.

Research output: Contribution to journalArticle

Cappola, AR, Desai, AS, Medici, M, Cooper, LS, Egan, D, Sopko, G, Fishman, GI, Goldman, S, Cooper, DS, Mora, S, Kudenchuk, PJ, Hollenberg, AN, McDonald, CL & Ladenson, PW 2019, 'Thyroid and Cardiovascular Disease: Research Agenda for Enhancing Knowledge, Prevention, and Treatment', Thyroid, vol. 29, no. 6, pp. 760-777. https://doi.org/10.1089/thy.2018.0416
Cappola, Anne R. ; Desai, Akshay S. ; Medici, Marco ; Cooper, Lawton S. ; Egan, Debra ; Sopko, George ; Fishman, Glenn I. ; Goldman, Steven ; Cooper, David S. ; Mora, Samia ; Kudenchuk, Peter J. ; Hollenberg, Anthony N. ; McDonald, Cheryl L. ; Ladenson, Paul W. / Thyroid and Cardiovascular Disease : Research Agenda for Enhancing Knowledge, Prevention, and Treatment. In: Thyroid. 2019 ; Vol. 29, No. 6. pp. 760-777.
@article{4265d748059c4b4f864c824b4d4854c9,
title = "Thyroid and Cardiovascular Disease: Research Agenda for Enhancing Knowledge, Prevention, and Treatment",
abstract = "Thyroid hormones have long been known to have a range of effects on the cardiovascular system. However, significant knowledge gaps exist concerning the precise molecular and biochemical mechanisms governing these effects and the optimal strategies for management of abnormalities in thyroid function in patients with and without preexisting cardiovascular disease. In September 2017, The National Heart, Lung, and Blood Institute convened a Working Group with the goal of developing priorities for future scientific research relating thyroid dysfunction to the progression of cardiovascular disease. The Working Group reviewed and discussed the roles of normal thyroid physiology, the consequences of thyroid dysfunction, and the effects of therapy in three cardiovascular areas: cardiac electrophysiology and arrhythmias, the vasculature and atherosclerosis, and the myocardium and heart failure. This report describes the current state of the field, outlines barriers and challenges to progress, and proposes research opportunities to advance the field, including strategies for leveraging novel approaches using omics and big data. The Working Group recommended research in three broad areas: 1) investigation into the fundamental biology relating thyroid dysfunction to the development of cardiovascular disease and into the identification of novel biomarkers of thyroid hormone action in cardiovascular tissues; 2) studies that define subgroups of patients with thyroid dysfunction amenable to specific preventive strategies and interventional therapies related to cardiovascular disease; and 3) clinical trials focused on improvement in cardiovascular performance and cardiovascular outcomes through treatment with thyroid hormone or thyromimetic drugs.",
keywords = "arrhythmia, atherosclerosis, heart failure, lipid, low T3 syndrome, subclinical hyperthyroidism, subclinical hypothyroidism",
author = "Cappola, {Anne R.} and Desai, {Akshay S.} and Marco Medici and Cooper, {Lawton S.} and Debra Egan and George Sopko and Fishman, {Glenn I.} and Steven Goldman and Cooper, {David S.} and Samia Mora and Kudenchuk, {Peter J.} and Hollenberg, {Anthony N.} and McDonald, {Cheryl L.} and Ladenson, {Paul W.}",
year = "2019",
month = "6",
day = "1",
doi = "10.1089/thy.2018.0416",
language = "English (US)",
volume = "29",
pages = "760--777",
journal = "Thyroid",
issn = "1050-7256",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Thyroid and Cardiovascular Disease

T2 - Research Agenda for Enhancing Knowledge, Prevention, and Treatment

AU - Cappola, Anne R.

AU - Desai, Akshay S.

AU - Medici, Marco

AU - Cooper, Lawton S.

AU - Egan, Debra

AU - Sopko, George

AU - Fishman, Glenn I.

AU - Goldman, Steven

AU - Cooper, David S.

AU - Mora, Samia

AU - Kudenchuk, Peter J.

AU - Hollenberg, Anthony N.

AU - McDonald, Cheryl L.

AU - Ladenson, Paul W.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Thyroid hormones have long been known to have a range of effects on the cardiovascular system. However, significant knowledge gaps exist concerning the precise molecular and biochemical mechanisms governing these effects and the optimal strategies for management of abnormalities in thyroid function in patients with and without preexisting cardiovascular disease. In September 2017, The National Heart, Lung, and Blood Institute convened a Working Group with the goal of developing priorities for future scientific research relating thyroid dysfunction to the progression of cardiovascular disease. The Working Group reviewed and discussed the roles of normal thyroid physiology, the consequences of thyroid dysfunction, and the effects of therapy in three cardiovascular areas: cardiac electrophysiology and arrhythmias, the vasculature and atherosclerosis, and the myocardium and heart failure. This report describes the current state of the field, outlines barriers and challenges to progress, and proposes research opportunities to advance the field, including strategies for leveraging novel approaches using omics and big data. The Working Group recommended research in three broad areas: 1) investigation into the fundamental biology relating thyroid dysfunction to the development of cardiovascular disease and into the identification of novel biomarkers of thyroid hormone action in cardiovascular tissues; 2) studies that define subgroups of patients with thyroid dysfunction amenable to specific preventive strategies and interventional therapies related to cardiovascular disease; and 3) clinical trials focused on improvement in cardiovascular performance and cardiovascular outcomes through treatment with thyroid hormone or thyromimetic drugs.

AB - Thyroid hormones have long been known to have a range of effects on the cardiovascular system. However, significant knowledge gaps exist concerning the precise molecular and biochemical mechanisms governing these effects and the optimal strategies for management of abnormalities in thyroid function in patients with and without preexisting cardiovascular disease. In September 2017, The National Heart, Lung, and Blood Institute convened a Working Group with the goal of developing priorities for future scientific research relating thyroid dysfunction to the progression of cardiovascular disease. The Working Group reviewed and discussed the roles of normal thyroid physiology, the consequences of thyroid dysfunction, and the effects of therapy in three cardiovascular areas: cardiac electrophysiology and arrhythmias, the vasculature and atherosclerosis, and the myocardium and heart failure. This report describes the current state of the field, outlines barriers and challenges to progress, and proposes research opportunities to advance the field, including strategies for leveraging novel approaches using omics and big data. The Working Group recommended research in three broad areas: 1) investigation into the fundamental biology relating thyroid dysfunction to the development of cardiovascular disease and into the identification of novel biomarkers of thyroid hormone action in cardiovascular tissues; 2) studies that define subgroups of patients with thyroid dysfunction amenable to specific preventive strategies and interventional therapies related to cardiovascular disease; and 3) clinical trials focused on improvement in cardiovascular performance and cardiovascular outcomes through treatment with thyroid hormone or thyromimetic drugs.

KW - arrhythmia

KW - atherosclerosis

KW - heart failure

KW - lipid

KW - low T3 syndrome

KW - subclinical hyperthyroidism

KW - subclinical hypothyroidism

UR - http://www.scopus.com/inward/record.url?scp=85066958868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066958868&partnerID=8YFLogxK

U2 - 10.1089/thy.2018.0416

DO - 10.1089/thy.2018.0416

M3 - Article

C2 - 31081673

AN - SCOPUS:85066958868

VL - 29

SP - 760

EP - 777

JO - Thyroid

JF - Thyroid

SN - 1050-7256

IS - 6

ER -